Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. - Wikidata - wikimedia - TriplyDB

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

http://www.wikidata.org/entity/Q43264239

about

The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for hum Advanced gastric cancer: Current treatment landscape and future perspectives Clinical modalities for management of gastric cancer hepatic metastasis Chemotherapy in Elderly Patients with Gastric Cancer Recent aspects for disseminated carcinomatosis of the bone marrow associated with gastric cancer: What has been done for the past, and what will be needed in future?Clinical utility of ramucirumab in advanced gastric cancer Perspectives in the treatment of pancreatic adenocarcinoma Clinical applications of 5-aminolevulinic acid-mediated fluorescence for gastric cancer S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials.A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures.Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study.Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials.Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis.Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer.Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma.Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study.Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis.Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis.Prognostic factors in stage IB gastric cancer.Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis.Eight-year survival after advanced gastric cancer treated with S-1 followed by surgery.Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.Molecular targeting to treat gastric cancer.Recent advances in chemotherapy for advanced gastric cancer Successful curative resection of gallbladder cancer following S-1 chemotherapy: A case report and review of the literature.S-1 in the treatment of pancreatic cancer.Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.

P2860

Q24633301-50A16CBA-0A58-4091-BB0D-97B96D918389 Q26764934-9800F07B-30EE-4044-B2E2-8CFCA0882CF4 Q26765314-54F7BC8A-A12B-4653-8D2A-AF86CA436791 Q26771424-5987548E-41D9-433F-B2C2-1493F15011DC Q26775945-08485239-ADD4-4C49-A242-923464631D86 Q26785665-19F5041A-9F4E-4CE0-9799-BA2D197E47BB Q26797248-86CF4DA3-7EC5-48D1-AED2-B87F3CB6A0A8 Q26798303-67307D3F-AA21-41D4-9963-6EF925488875 Q27002415-EA3FECDA-7A5A-4962-A663-BDE7BBFAAD2F Q27318805-DE71A2C5-830F-49D8-ABD1-12CCCE7E9E34 Q30785622-AAC9505E-3470-4140-8ADD-8CB3EE0AF7C6 Q30834530-9934599A-644B-4D61-81C4-BDFE8BE6DD6C Q31162395-CD0F9981-0AAF-4A2E-BF18-168BEC26482E Q33391729-60EFDA54-0D19-4BB2-8EFF-4C4803C8297D Q33395721-45C71D3E-123A-4812-8BF4-6D6C2AF1086A Q33398969-E6A51570-DEE2-43E8-93C9-EF19389A751F Q33400558-D5AA7847-B3F8-4E60-B972-F1C7FD6F7182 Q33407844-91F4D94A-947E-4037-A42F-3C2C3A3065D6 Q33415440-EF85C2BA-E1A4-46BC-9BCB-3DADA7634C10 Q33416158-2C660385-3804-492B-8A18-09E45105C7AF Q33420157-E27CB06D-0192-40B1-9E0B-DC188975B2E4 Q33425150-9FDC7353-2E89-4DD9-9DB8-77D438A512C2 Q33428967-B6BB930A-FE8E-446E-BB21-8136834711E4 Q33433129-FC73D7EE-5526-4BF5-BC4B-6D735A22E848 Q33437668-BAB4823B-6670-4FCC-B3E4-51F23C2C3EF4 Q33442681-CF2F326D-3141-4603-8B84-7A96B5EE71B6 Q33574315-8856124A-23B0-42AD-A23C-C2EFA32BB474 Q33594906-F0C0BE77-8DE3-4718-9123-C44E61A498C5 Q33605846-D70EC732-011A-42E4-BD74-51F76716A07D Q33718311-B32175FF-93AE-4F3C-9BA1-1FD9D36FF786 Q33728364-B99A5DF5-55FB-48FF-9415-50362B5ED080 Q33889328-8D964242-1778-42BF-A419-B20BF6C07BBD Q33903658-FB636BD7-24AA-4E9D-85E7-6BFBBE25E520 Q33912151-D77A061A-771C-47A8-87A9-AD74B5DFD5CB Q34086875-56CB8ECF-FB69-4501-B1F0-9E2709D333DC Q34326593-40021DA9-1A83-4AEE-AB74-5EC75B894CDE Q34389753-1BF777AC-898B-4D22-8798-60B3C34C8531 Q34427188-4F35CCE3-1A30-43E1-B55B-6333BC96A552 Q34467156-6B0EC90D-CEE5-4C68-B64C-A48BA8FA20DC Q34608899-C79AA9B5-44B1-41D2-B8FC-92FBAA58B224

P2860

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

http://www.wikidata.org/entity/Q43264239

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Fluorouracil versus combinatio ...... r: a randomised phase 3 study.

@en

Fluorouracil versus combinatio ...... r: a randomised phase 3 study.

@nl

type

label

Fluorouracil versus combinatio ...... r: a randomised phase 3 study.

@en

Fluorouracil versus combinatio ...... r: a randomised phase 3 study.

@nl

prefLabel

Fluorouracil versus combinatio ...... r: a randomised phase 3 study.

@en

Fluorouracil versus combinatio ...... r: a randomised phase 3 study.

@nl

P1433

Q43264239-50C303D4-E096-44C0-B277-DE898E4D45D7

P1476

Q43264239-622B5CE0-9CA5-4E3C-85CC-9806706593E5

P2093

Q43264239-1D5341E3-2619-4C5A-93D2-622FD7E41F75

Q43264239-414372FF-D47F-496F-B2DF-A93CF5FE8536

Q43264239-5BA5D3EA-CD35-41DB-A2BC-09CC32FA1B2C

Q43264239-68C72DA6-62D0-406A-83AD-A40944950D41

Q43264239-86E570B2-098B-4FC8-974A-DE1F155A0A69

Q43264239-9F4FBA31-7F0C-4875-92DD-93C007040479

Q43264239-A9AA7510-6C12-4BA7-9AC0-C08DAA340836

Q43264239-B2AA0B45-475B-441A-B213-70A90435E463

Q43264239-B8BDB8C8-66B1-4C45-95AF-1EBD1FE49BB9

Q43264239-BB1F96D2-C3B3-4C36-89EB-3A1DACCE8B83

P304

Q43264239-3EBA7AF1-CC68-45E1-88A6-936383A44037

P31

Q43264239-4C21B4A8-2216-4FD0-AD2A-0438B429A291

P356

Q43264239-A77B0B32-2271-42F9-9766-65A45084FBE5

P433

Q43264239-614D7BDB-179D-4CE7-B346-5426BD6AFEFA

P478

Q43264239-7C00E482-125A-4A66-84A2-B263C876BC7C

P50

Q43264239-47F21F64-5724-4E3A-9372-B0E9194071A6

P577

Q43264239-6F0E8830-B1A0-4BA1-91A8-D3B3F02287C9

P698

Q43264239-2FC5D16C-A1EF-41F3-9AD9-3BE57CE9A823

P356

S1470-2045(09)70259-1

P1433

The Lancet Oncology

P1476

Fluorouracil versus combinatio ...... r: a randomised phase 3 study.

@en

P2093

Akira Sawaki

http://www.w3.org/2001/XMLSchema#string

Atsushi Ohtsu

http://www.w3.org/2001/XMLSchema#string

Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group

http://www.w3.org/2001/XMLSchema#string

Haruhiko Fukuda

http://www.w3.org/2001/XMLSchema#string

Hiroshi Saito

http://www.w3.org/2001/XMLSchema#string

Hiroya Takiuchi

http://www.w3.org/2001/XMLSchema#string

Junichiro Nasu

http://www.w3.org/2001/XMLSchema#string

Kensei Yamaguchi

http://www.w3.org/2001/XMLSchema#string

Kuniaki Shirao

http://www.w3.org/2001/XMLSchema#string

Narikazu Boku

http://www.w3.org/2001/XMLSchema#string

P304

1063-1069

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(09)70259-1

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19818685

http://www.w3.org/2001/XMLSchema#string